English

AIM IMMUNOTECH INC.

EDGAR

AIM Quarterly report (10-Q) · filed 2026-08-07

Annual consolidated revenue for 2025: about USD 88K, using the latest reported figures. The previous period, 2024, was about USD 170K.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

26 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 26000 USD Source

Operating margin

-13,511.54%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -3513000 USD Source
Revenue: 26000 USD Source

Operating cash flow

-4.59 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -7309000 USD Source
Operating Cash Flow: -2719000 USD Source

Cash and cash equivalents: 9.9 million USD 2026-06-30 Source
Exact value

9900000 USD
Long-term debt including current maturities: 3.62 million USD 2026-06-30 Source
Exact value

3621000 USD
Shares outstanding: 29 million shares 2026-06-30 Source
Exact value

28990073 shares

Reported share-count change

3,693.58% · 28.2 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

764188 shares · 2025-06-30· Source
28990073 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

95 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 26000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 88000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 67000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 22000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 26000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-14.3 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -3284000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -13958000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -9783000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -3023000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -3788000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-14.4 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -8971000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -3892000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -10957000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -8971000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -2719000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -7309000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -2719000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-07.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 9 of 11 periods available· newest 2024-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 4 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 5 of 11 periods available· newest 2025-12-31
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-48.2%

Prior period

USD 170,000

2024-01-01 – 2024-12-31
Current period

USD 88,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

88000 − 170000 = -82000 USD

170000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
88000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · AIM IMMUNOTECH INC. · 2025-12-31 AIM IMMUNOTECH INC. (edgar:946644) Year-over-year change in Revenue: -82000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 88000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/form10-k.htm#1835719 Filing: 000149315226013301 Input fundies:Revenue: 170000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/form10-k.htm#1836147 Filing: 000149315226013301
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 3.36 million

Prior period

−USD 17.32 million

2024-01-01 – 2024-12-31
Current period

−USD 13.96 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-13958000 − -17320000 = 3362000 USD

-17320000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-13958000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · AIM IMMUNOTECH INC. · 2025-12-31 AIM IMMUNOTECH INC. (edgar:946644) Year-over-year change in Net income: 3362000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -13958000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/form10-k.htm#1912858 Filing: 000149315226013301 Input fundies:NetIncome: -17320000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/form10-k.htm#1913234 Filing: 000149315226013301
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 3.93 million

Prior period

−USD 14.89 million

2024-01-01 – 2024-12-31
Current period

−USD 10.96 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-10957000 − -14888000 = 3931000 USD

-14888000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-10957000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · AIM IMMUNOTECH INC. · 2025-12-31 AIM IMMUNOTECH INC. (edgar:946644) Year-over-year change in Operating cash flow: 3931000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -10957000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/form10-k.htm#1930714 Filing: 000149315226013301 Input fundies:OperatingCashFlow: -14888000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/form10-k.htm#1931185 Filing: 000149315226013301
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 88,000 100% of revenue
Operating costs Derived USD 11.75 million 13,355% of revenue
Operating income −USD 11.66 million −13,255% of revenue
Tax, interest and other Derived USD 2.29 million 2,607% of revenue
Net income −USD 13.96 million −15,861% of revenue

Cash

Operating cash flow −USD 10.96 million −12,451% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 15,104% of revenue.
2017 Operating loss: operating costs were 2,712% of revenue.
2018 Operating loss: operating costs were 3,232% of revenue.
2019 Operating loss: operating costs were 8,988% of revenue.
2020 Operating loss: operating costs were 9,396% of revenue.
2021 Operating loss: operating costs were 14,054% of revenue.
2022 Operating loss: operating costs were 14,230% of revenue.
2023 Operating loss: operating costs were 15,900% of revenue.
2024 Operating loss: operating costs were 11,731% of revenue.
2025 Operating loss: operating costs were 13,355% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	92000	13896000 Derived	-13804000	-6302000 Derived	-7502000	-7540000 Derived	Source 2016-01-01 – 2016-12-31: 92000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -13804000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -7502000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -7380000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 160000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	437000	11853000 Derived	-11416000	-3157000 Derived	-8259000	-7961000 Derived	Source 2017-01-01 – 2017-12-31: 437000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -11416000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -8259000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -7941000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 20000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	367000	11863000 Derived	-11496000	-1669000 Derived	-9827000	-10691000 Derived	Source 2018-01-01 – 2018-12-31: 367000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -11496000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -9827000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -10640000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 51000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	140000	12583000 Derived	-12443000	-3039000 Derived	-9404000	-9135000 Derived	Source 2019-01-01 – 2019-12-31: 140000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -12443000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -9404000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -9067000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 68000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	163000	15315000 Derived	-15152000	-752000 Derived	-14400000	-10390000 Derived	Source 2020-01-01 – 2020-12-31: 163000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -15152000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -14400000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -10368000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 22000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	135000	18973000 Derived	-18838000	289000 Derived	-19127000	-14006000 Derived	Source 2021-01-01 – 2021-12-31: 135000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -18838000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -19127000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -13965000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 41000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	141000	20064000 Derived	-19923000	-478000 Derived	-19445000	-16194000 Derived	Source 2022-01-01 – 2022-12-31: 141000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -19923000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -19445000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -16108000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 86000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	202000	32118000 Derived	-31916000	-2954000 Derived	-28962000	Unavailable	Source 2023-01-01 – 2023-12-31: 202000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -31916000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -28962000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -21267000 USD Inspect Operating Cash Flow Open source
2024 2024-01-01 – 2024-12-31	170000	19942000 Derived	-19772000	-2452000 Derived	-17320000	-14906000 Derived	Source 2024-01-01 – 2024-12-31: 170000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -19772000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -17320000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -14888000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 18000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	88000	11752000 Derived	-11664000	2294000 Derived	-13958000	Unavailable	Source 2025-01-01 – 2025-12-31: 88000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -11664000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -13958000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -10957000 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 88K 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	92000	Revenue: 92000 Open source
20172017-12-31	Revenue	437000	Revenue: 437000 Open source
20182018-12-31	Revenue	367000	Revenue: 367000 Open source
20192019-12-31	Revenue	140000	Revenue: 140000 Open source
20202020-12-31	Revenue	163000	Revenue: 163000 Open source
20212021-12-31	Revenue	135000	Revenue: 135000 Open source
20222022-12-31	Revenue	141000	Revenue: 141000 Open source
20232023-12-31	Revenue	202000	Revenue: 202000 Open source
20242024-12-31	Revenue	170000	Revenue: 170000 Open source
20252025-12-31	Revenue	88000	Revenue: 88000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-48.2% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	-30.8%	Revenue: 92000 Open source Revenue: 133000 Open source
20172017-12-31	Year over year	375%	Revenue: 437000 Open source Revenue: 92000 Open source
20182018-12-31	Year over year	-16%	Revenue: 367000 Open source Revenue: 437000 Open source
20192019-12-31	Year over year	-61.9%	Revenue: 140000 Open source Revenue: 367000 Open source
20202020-12-31	Year over year	16.4%	Revenue: 163000 Open source Revenue: 140000 Open source
20212021-12-31	Year over year	-17.2%	Revenue: 135000 Open source Revenue: 163000 Open source
20222022-12-31	Year over year	4.4%	Revenue: 141000 Open source Revenue: 135000 Open source
20232023-12-31	Year over year	43.3%	Revenue: 202000 Open source Revenue: 141000 Open source
20242024-12-31	Year over year	-15.8%	Revenue: 170000 Open source Revenue: 202000 Open source
20252025-12-31	Year over year	-48.2%	Revenue: 88000 Open source Revenue: 170000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -13,254.5% 2025

Net margin -15,861.4% 2025

Free cash flow margin -8,768.2% 2024

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-15,004.3%	Operating Income: -13804000 Open source Revenue: 92000 Open source
20172017-12-31	Operating margin	-2,612.4%	Operating Income: -11416000 Open source Revenue: 437000 Open source
20182018-12-31	Operating margin	-3,132.4%	Operating Income: -11496000 Open source Revenue: 367000 Open source
20192019-12-31	Operating margin	-8,887.9%	Operating Income: -12443000 Open source Revenue: 140000 Open source
20202020-12-31	Operating margin	-9,295.7%	Operating Income: -15152000 Open source Revenue: 163000 Open source
20212021-12-31	Operating margin	-13,954.1%	Operating Income: -18838000 Open source Revenue: 135000 Open source
20222022-12-31	Operating margin	-14,129.8%	Operating Income: -19923000 Open source Revenue: 141000 Open source
20232023-12-31	Operating margin	-15,800%	Operating Income: -31916000 Open source Revenue: 202000 Open source
20242024-12-31	Operating margin	-11,630.6%	Operating Income: -19772000 Open source Revenue: 170000 Open source
20252025-12-31	Operating margin	-13,254.5%	Operating Income: -11664000 Open source Revenue: 88000 Open source
20162016-12-31	Net margin	-8,154.3%	Net Income: -7502000 Open source Revenue: 92000 Open source
20172017-12-31	Net margin	-1,889.9%	Net Income: -8259000 Open source Revenue: 437000 Open source
20182018-12-31	Net margin	-2,677.7%	Net Income: -9827000 Open source Revenue: 367000 Open source
20192019-12-31	Net margin	-6,717.1%	Net Income: -9404000 Open source Revenue: 140000 Open source
20202020-12-31	Net margin	-8,834.4%	Net Income: -14400000 Open source Revenue: 163000 Open source
20212021-12-31	Net margin	-14,168.1%	Net Income: -19127000 Open source Revenue: 135000 Open source
20222022-12-31	Net margin	-13,790.8%	Net Income: -19445000 Open source Revenue: 141000 Open source
20232023-12-31	Net margin	-14,337.6%	Net Income: -28962000 Open source Revenue: 202000 Open source
20242024-12-31	Net margin	-10,188.2%	Net Income: -17320000 Open source Revenue: 170000 Open source
20252025-12-31	Net margin	-15,861.4%	Net Income: -13958000 Open source Revenue: 88000 Open source
20162016-12-31	Free cash flow margin	-8,195.7%	Revenue: 92000 Open source Operating Cash Flow: -7380000 Open source Capital Expenditure: 160000 Open source
20172017-12-31	Free cash flow margin	-1,821.7%	Revenue: 437000 Open source Operating Cash Flow: -7941000 Open source Capital Expenditure: 20000 Open source
20182018-12-31	Free cash flow margin	-2,913.1%	Revenue: 367000 Open source Operating Cash Flow: -10640000 Open source Capital Expenditure: 51000 Open source
20192019-12-31	Free cash flow margin	-6,525%	Revenue: 140000 Open source Operating Cash Flow: -9067000 Open source Capital Expenditure: 68000 Open source
20202020-12-31	Free cash flow margin	-6,374.2%	Revenue: 163000 Open source Operating Cash Flow: -10368000 Open source Capital Expenditure: 22000 Open source
20212021-12-31	Free cash flow margin	-10,374.8%	Revenue: 135000 Open source Operating Cash Flow: -13965000 Open source Capital Expenditure: 41000 Open source
20222022-12-31	Free cash flow margin	-11,485.1%	Revenue: 141000 Open source Operating Cash Flow: -16108000 Open source Capital Expenditure: 86000 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 202000 Open source Operating Cash Flow: -21267000 Open source
20242024-12-31	Free cash flow margin	-8,768.2%	Revenue: 170000 Open source Operating Cash Flow: -14888000 Open source Capital Expenditure: 18000 Open source
20252025-12-31	Free cash flow margin	Not reported	Revenue: 88000 Open source Operating Cash Flow: -10957000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -11M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-7380000	Operating Cash Flow: -7380000 Open source
20172017-12-31	Operating cash flow	-7941000	Operating Cash Flow: -7941000 Open source
20182018-12-31	Operating cash flow	-10640000	Operating Cash Flow: -10640000 Open source
20192019-12-31	Operating cash flow	-9067000	Operating Cash Flow: -9067000 Open source
20202020-12-31	Operating cash flow	-10368000	Operating Cash Flow: -10368000 Open source
20212021-12-31	Operating cash flow	-13965000	Operating Cash Flow: -13965000 Open source
20222022-12-31	Operating cash flow	-16108000	Operating Cash Flow: -16108000 Open source
20232023-12-31	Operating cash flow	-21267000	Operating Cash Flow: -21267000 Open source
20242024-12-31	Operating cash flow	-14888000	Operating Cash Flow: -14888000 Open source
20252025-12-31	Operating cash flow	-10957000	Operating Cash Flow: -10957000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -14.9M 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-7540000	Operating Cash Flow: -7380000 Open source Capital Expenditure: 160000 Open source
20172017-12-31	Free cash flow	-7961000	Operating Cash Flow: -7941000 Open source Capital Expenditure: 20000 Open source
20182018-12-31	Free cash flow	-10691000	Operating Cash Flow: -10640000 Open source Capital Expenditure: 51000 Open source
20192019-12-31	Free cash flow	-9135000	Operating Cash Flow: -9067000 Open source Capital Expenditure: 68000 Open source
20202020-12-31	Free cash flow	-10390000	Operating Cash Flow: -10368000 Open source Capital Expenditure: 22000 Open source
20212021-12-31	Free cash flow	-14006000	Operating Cash Flow: -13965000 Open source Capital Expenditure: 41000 Open source
20222022-12-31	Free cash flow	-16194000	Operating Cash Flow: -16108000 Open source Capital Expenditure: 86000 Open source
20232023-12-31	Free cash flow	Unavailable	Operating Cash Flow: -21267000 Open source
20242024-12-31	Free cash flow	-14906000	Operating Cash Flow: -14888000 Open source Capital Expenditure: 18000 Open source
20252025-12-31	Free cash flow	Unavailable	Operating Cash Flow: -10957000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

269.2% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2016-12-31	Liabilities / assets	Not reported	Total Assets: 18873000 Open source
2017-12-31	Liabilities / assets	Not reported	Total Assets: 14207000 Open source
2018-12-31	Liabilities / assets	Not reported	Total Assets: 13845000 Open source
2019-12-31	Liabilities / assets	Not reported	Total Assets: 20754000 Open source
2020-12-31	Liabilities / assets	Not reported	Total Assets: 64584000 Open source
2021-12-31	Liabilities / assets	Not reported	Total Assets: 57699000 Open source
20222022-12-31	Liabilities / assets	5%	Total Liabilities: 2020000 Open source Total Assets: 40488000 Open source
20232023-12-31	Liabilities / assets	47.2%	Total Liabilities: 9147000 Open source Total Assets: 19381000 Open source
20242024-12-31	Liabilities / assets	115.4%	Total Liabilities: 9930000 Open source Total Assets: 8608000 Open source
20252025-12-31	Liabilities / assets	269.2%	Total Liabilities: 15565000 Open source Total Assets: 5782000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.53× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	2.85×	Current Assets: 6941000 Open source Current Liabilities: 2435000 Open source
20172017-12-31	Current assets / current liabilities	1.29×	Current Assets: 3505000 Open source Current Liabilities: 2707000 Open source
20182018-12-31	Current assets / current liabilities	0.72×	Current Assets: 3799000 Open source Current Liabilities: 5292000 Open source
20192019-12-31	Current assets / current liabilities	9.27×	Current Assets: 10446000 Open source Current Liabilities: 1127000 Open source
20202020-12-31	Current assets / current liabilities	36.58×	Current Assets: 40310000 Open source Current Liabilities: 1102000 Open source
20212021-12-31	Current assets / current liabilities	74.61×	Current Assets: 50213000 Open source Current Liabilities: 673000 Open source
20222022-12-31	Current assets / current liabilities	26.69×	Current Assets: 36321000 Open source Current Liabilities: 1361000 Open source
20232023-12-31	Current assets / current liabilities	1.68×	Current Assets: 14556000 Open source Current Liabilities: 8652000 Open source
20242024-12-31	Current assets / current liabilities	0.44×	Current Assets: 4176000 Open source Current Liabilities: 9535000 Open source
20252025-12-31	Current assets / current liabilities	0.53×	Current Assets: 3295000 Open source Current Liabilities: 6224000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 7.5 million Exact value Exact value: -7502000 USD 2016-01-01 – 2016-12-31: -7502000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AIM IMMUNOTECH INC. · 2016-12-31 AIM IMMUNOTECH INC. (edgar:946644) Net Income: -7502000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7502000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315218004291/heb-20171231.xml#238980 Filing: 000149315218004291 The citation records this snapshot. The page link may show a newer release later.	−USD 7.38 million Exact value Exact value: -7380000 USD 2016-01-01 – 2016-12-31: -7380000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AIM IMMUNOTECH INC. · 2016-12-31 AIM IMMUNOTECH INC. (edgar:946644) Operating Cash Flow: -7380000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7380000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315218004291/heb-20171231.xml#234016 Filing: 000149315218004291 The citation records this snapshot. The page link may show a newer release later.	USD 160,000 Exact value Exact value: 160000 USD 2016-01-01 – 2016-12-31: 160000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AIM IMMUNOTECH INC. · 2016-12-31 AIM IMMUNOTECH INC. (edgar:946644) Capital Expenditure: 160000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 160000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315218004291/heb-20171231.xml#234569 Filing: 000149315218004291 The citation records this snapshot. The page link may show a newer release later.	−USD 7.54 million Calculation and evidence -7380000 − 160000 USD Exact free cash flow: -7540000 USD 2016-01-01 – 2016-12-31: -7380000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 160000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AIM IMMUNOTECH INC. · 2016-12-31 AIM IMMUNOTECH INC. (edgar:946644) Free cash flow: -7540000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7380000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315218004291/heb-20171231.xml#234016 Filing: 000149315218004291 Input fundies:CapitalExpenditure: 160000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315218004291/heb-20171231.xml#234569 Filing: 000149315218004291 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 8.26 million Exact value Exact value: -8259000 USD 2017-01-01 – 2017-12-31: -8259000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AIM IMMUNOTECH INC. · 2017-12-31 AIM IMMUNOTECH INC. (edgar:946644) Net Income: -8259000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -8259000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315219004583/heb-20181231.xml#409425 Filing: 000149315219004583 The citation records this snapshot. The page link may show a newer release later.	−USD 7.94 million Exact value Exact value: -7941000 USD 2017-01-01 – 2017-12-31: -7941000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AIM IMMUNOTECH INC. · 2017-12-31 AIM IMMUNOTECH INC. (edgar:946644) Operating Cash Flow: -7941000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7941000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315219004583/heb-20181231.xml#445158 Filing: 000149315219004583 The citation records this snapshot. The page link may show a newer release later.	USD 20,000 Exact value Exact value: 20000 USD 2017-01-01 – 2017-12-31: 20000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AIM IMMUNOTECH INC. · 2017-12-31 AIM IMMUNOTECH INC. (edgar:946644) Capital Expenditure: 20000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 20000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315219004583/heb-20181231.xml#445925 Filing: 000149315219004583 The citation records this snapshot. The page link may show a newer release later.	−USD 7.96 million Calculation and evidence -7941000 − 20000 USD Exact free cash flow: -7961000 USD 2017-01-01 – 2017-12-31: -7941000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 20000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AIM IMMUNOTECH INC. · 2017-12-31 AIM IMMUNOTECH INC. (edgar:946644) Free cash flow: -7961000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7941000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315219004583/heb-20181231.xml#445158 Filing: 000149315219004583 Input fundies:CapitalExpenditure: 20000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315219004583/heb-20181231.xml#445925 Filing: 000149315219004583 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 9.83 million Exact value Exact value: -9827000 USD 2018-01-01 – 2018-12-31: -9827000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AIM IMMUNOTECH INC. · 2018-12-31 AIM IMMUNOTECH INC. (edgar:946644) Net Income: -9827000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -9827000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315220005290/aim-20191231.xml#324404 Filing: 000149315220005290 The citation records this snapshot. The page link may show a newer release later.	−USD 10.64 million Exact value Exact value: -10640000 USD 2018-01-01 – 2018-12-31: -10640000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AIM IMMUNOTECH INC. · 2018-12-31 AIM IMMUNOTECH INC. (edgar:946644) Operating Cash Flow: -10640000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10640000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315220005290/aim-20191231.xml#382984 Filing: 000149315220005290 The citation records this snapshot. The page link may show a newer release later.	USD 51,000 Exact value Exact value: 51000 USD 2018-01-01 – 2018-12-31: 51000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AIM IMMUNOTECH INC. · 2018-12-31 AIM IMMUNOTECH INC. (edgar:946644) Capital Expenditure: 51000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 51000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315220005290/aim-20191231.xml#383354 Filing: 000149315220005290 The citation records this snapshot. The page link may show a newer release later.	−USD 10.69 million Calculation and evidence -10640000 − 51000 USD Exact free cash flow: -10691000 USD 2018-01-01 – 2018-12-31: -10640000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 51000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AIM IMMUNOTECH INC. · 2018-12-31 AIM IMMUNOTECH INC. (edgar:946644) Free cash flow: -10691000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10640000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315220005290/aim-20191231.xml#382984 Filing: 000149315220005290 Input fundies:CapitalExpenditure: 51000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315220005290/aim-20191231.xml#383354 Filing: 000149315220005290 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 9.4 million Exact value Exact value: -9404000 USD 2019-01-01 – 2019-12-31: -9404000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AIM IMMUNOTECH INC. · 2019-12-31 AIM IMMUNOTECH INC. (edgar:946644) Net Income: -9404000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -9404000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315221007259/aim-20201231.xml#359501 Filing: 000149315221007259 The citation records this snapshot. The page link may show a newer release later.	−USD 9.07 million Exact value Exact value: -9067000 USD 2019-01-01 – 2019-12-31: -9067000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AIM IMMUNOTECH INC. · 2019-12-31 AIM IMMUNOTECH INC. (edgar:946644) Operating Cash Flow: -9067000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9067000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315221007259/aim-20201231.xml#355965 Filing: 000149315221007259 The citation records this snapshot. The page link may show a newer release later.	USD 68,000 Exact value Exact value: 68000 USD 2019-01-01 – 2019-12-31: 68000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AIM IMMUNOTECH INC. · 2019-12-31 AIM IMMUNOTECH INC. (edgar:946644) Capital Expenditure: 68000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 68000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315221007259/aim-20201231.xml#354887 Filing: 000149315221007259 The citation records this snapshot. The page link may show a newer release later.	−USD 9.14 million Calculation and evidence -9067000 − 68000 USD Exact free cash flow: -9135000 USD 2019-01-01 – 2019-12-31: -9067000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 68000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AIM IMMUNOTECH INC. · 2019-12-31 AIM IMMUNOTECH INC. (edgar:946644) Free cash flow: -9135000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -9067000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315221007259/aim-20201231.xml#355965 Filing: 000149315221007259 Input fundies:CapitalExpenditure: 68000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315221007259/aim-20201231.xml#354887 Filing: 000149315221007259 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 14.4 million Exact value Exact value: -14400000 USD 2020-01-01 – 2020-12-31: -14400000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AIM IMMUNOTECH INC. · 2020-12-31 AIM IMMUNOTECH INC. (edgar:946644) Net Income: -14400000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14400000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315222008324/form10-k.htm#1373245 Filing: 000149315222008324 The citation records this snapshot. The page link may show a newer release later.	−USD 10.37 million Exact value Exact value: -10368000 USD 2020-01-01 – 2020-12-31: -10368000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AIM IMMUNOTECH INC. · 2020-12-31 AIM IMMUNOTECH INC. (edgar:946644) Operating Cash Flow: -10368000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10368000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315222008324/form10-k.htm#1398450 Filing: 000149315222008324 The citation records this snapshot. The page link may show a newer release later.	USD 22,000 Exact value Exact value: 22000 USD 2020-01-01 – 2020-12-31: 22000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AIM IMMUNOTECH INC. · 2020-12-31 AIM IMMUNOTECH INC. (edgar:946644) Capital Expenditure: 22000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 22000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315222008324/form10-k.htm#1402390 Filing: 000149315222008324 The citation records this snapshot. The page link may show a newer release later.	−USD 10.39 million Calculation and evidence -10368000 − 22000 USD Exact free cash flow: -10390000 USD 2020-01-01 – 2020-12-31: -10368000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 22000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AIM IMMUNOTECH INC. · 2020-12-31 AIM IMMUNOTECH INC. (edgar:946644) Free cash flow: -10390000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10368000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315222008324/form10-k.htm#1398450 Filing: 000149315222008324 Input fundies:CapitalExpenditure: 22000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315222008324/form10-k.htm#1402390 Filing: 000149315222008324 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 19.13 million Exact value Exact value: -19127000 USD 2021-01-01 – 2021-12-31: -19127000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AIM IMMUNOTECH INC. · 2021-12-31 AIM IMMUNOTECH INC. (edgar:946644) Net Income: -19127000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -19127000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315223010351/form10-k.htm#1421581 Filing: 000149315223010351 The citation records this snapshot. The page link may show a newer release later.	−USD 13.97 million Exact value Exact value: -13965000 USD 2021-01-01 – 2021-12-31: -13965000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AIM IMMUNOTECH INC. · 2021-12-31 AIM IMMUNOTECH INC. (edgar:946644) Operating Cash Flow: -13965000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13965000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315223010351/form10-k.htm#1439318 Filing: 000149315223010351 The citation records this snapshot. The page link may show a newer release later.	USD 41,000 Exact value Exact value: 41000 USD 2021-01-01 – 2021-12-31: 41000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AIM IMMUNOTECH INC. · 2021-12-31 AIM IMMUNOTECH INC. (edgar:946644) Capital Expenditure: 41000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 41000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315223010351/form10-k.htm#1442611 Filing: 000149315223010351 The citation records this snapshot. The page link may show a newer release later.	−USD 14.01 million Calculation and evidence -13965000 − 41000 USD Exact free cash flow: -14006000 USD 2021-01-01 – 2021-12-31: -13965000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 41000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AIM IMMUNOTECH INC. · 2021-12-31 AIM IMMUNOTECH INC. (edgar:946644) Free cash flow: -14006000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13965000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315223010351/form10-k.htm#1439318 Filing: 000149315223010351 Input fundies:CapitalExpenditure: 41000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315223010351/form10-k.htm#1442611 Filing: 000149315223010351 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 19.45 million Exact value Exact value: -19445000 USD 2022-01-01 – 2022-12-31: -19445000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AIM IMMUNOTECH INC. · 2022-12-31 AIM IMMUNOTECH INC. (edgar:946644) Net Income: -19445000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -19445000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315225003444/forms-1.htm#2952328 Filing: 000149315225003444 The citation records this snapshot. The page link may show a newer release later.	−USD 16.11 million Exact value Exact value: -16108000 USD 2022-01-01 – 2022-12-31: -16108000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AIM IMMUNOTECH INC. · 2022-12-31 AIM IMMUNOTECH INC. (edgar:946644) Operating Cash Flow: -16108000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -16108000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315225003444/forms-1.htm#2981105 Filing: 000149315225003444 The citation records this snapshot. The page link may show a newer release later.	USD 86,000 Exact value Exact value: 86000 USD 2022-01-01 – 2022-12-31: 86000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AIM IMMUNOTECH INC. · 2022-12-31 AIM IMMUNOTECH INC. (edgar:946644) Capital Expenditure: 86000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 86000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315225003444/forms-1.htm#2987173 Filing: 000149315225003444 The citation records this snapshot. The page link may show a newer release later.	−USD 16.19 million Calculation and evidence -16108000 − 86000 USD Exact free cash flow: -16194000 USD 2022-01-01 – 2022-12-31: -16108000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 86000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AIM IMMUNOTECH INC. · 2022-12-31 AIM IMMUNOTECH INC. (edgar:946644) Free cash flow: -16194000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -16108000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315225003444/forms-1.htm#2981105 Filing: 000149315225003444 Input fundies:CapitalExpenditure: 86000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315225003444/forms-1.htm#2987173 Filing: 000149315225003444 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 28.96 million Exact value Exact value: -28962000 USD 2023-01-01 – 2023-12-31: -28962000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AIM IMMUNOTECH INC. · 2023-12-31 AIM IMMUNOTECH INC. (edgar:946644) Net Income: -28962000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -28962000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000164117225000847/form10-k.htm#1494604 Filing: 000164117225000847 The citation records this snapshot. The page link may show a newer release later.	−USD 21.27 million Exact value Exact value: -21267000 USD 2023-01-01 – 2023-12-31: -21267000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AIM IMMUNOTECH INC. · 2023-12-31 AIM IMMUNOTECH INC. (edgar:946644) Operating Cash Flow: -21267000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -21267000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000164117225000847/form10-k.htm#1510777 Filing: 000164117225000847 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2024 2024-01-01 – 2024-12-31	−USD 17.32 million Exact value Exact value: -17320000 USD 2024-01-01 – 2024-12-31: -17320000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AIM IMMUNOTECH INC. · 2024-12-31 AIM IMMUNOTECH INC. (edgar:946644) Net Income: -17320000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17320000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/form10-k.htm#1913234 Filing: 000149315226013301 The citation records this snapshot. The page link may show a newer release later.	−USD 14.89 million Exact value Exact value: -14888000 USD 2024-01-01 – 2024-12-31: -14888000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AIM IMMUNOTECH INC. · 2024-12-31 AIM IMMUNOTECH INC. (edgar:946644) Operating Cash Flow: -14888000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14888000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/form10-k.htm#1931185 Filing: 000149315226013301 The citation records this snapshot. The page link may show a newer release later.	USD 18,000 Exact value Exact value: 18000 USD 2024-01-01 – 2024-12-31: 18000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AIM IMMUNOTECH INC. · 2024-12-31 AIM IMMUNOTECH INC. (edgar:946644) Capital Expenditure: 18000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 18000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/form10-k.htm#1934441 Filing: 000149315226013301 The citation records this snapshot. The page link may show a newer release later.	−USD 14.91 million Calculation and evidence -14888000 − 18000 USD Exact free cash flow: -14906000 USD 2024-01-01 – 2024-12-31: -14888000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 18000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AIM IMMUNOTECH INC. · 2024-12-31 AIM IMMUNOTECH INC. (edgar:946644) Free cash flow: -14906000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14888000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/form10-k.htm#1931185 Filing: 000149315226013301 Input fundies:CapitalExpenditure: 18000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/form10-k.htm#1934441 Filing: 000149315226013301 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 13.96 million Exact value Exact value: -13958000 USD 2025-01-01 – 2025-12-31: -13958000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AIM IMMUNOTECH INC. · 2025-12-31 AIM IMMUNOTECH INC. (edgar:946644) Net Income: -13958000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -13958000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/form10-k.htm#1912858 Filing: 000149315226013301 The citation records this snapshot. The page link may show a newer release later.	−USD 10.96 million Exact value Exact value: -10957000 USD 2025-01-01 – 2025-12-31: -10957000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AIM IMMUNOTECH INC. · 2025-12-31 AIM IMMUNOTECH INC. (edgar:946644) Operating Cash Flow: -10957000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/946644/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10957000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/form10-k.htm#1930714 Filing: 000149315226013301 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

352 filings · 3,907 latest values · 3,907 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000946644, 946644, AIM, HEB, edgar:946644

Also known as AIM IMMUNOTECH INC., AIM IMMUNOTECH INC., AIM ImmunoTech Inc., Aim ImmunoTech Inc., HEMISPHERX BIOPHARMA INC

AIM IMMUNOTECH INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation